Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Acute Respiratory Distress Syndrome: early-phase trial registry
14 of 32 indexed Acute Respiratory Distress Syndrome trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #477 of 28,707 conditions by registered trial count.
32 US clinical trials · 14 currently recruiting · #477 of 28,707 conditions by registered trial count
Acute Respiratory Distress Syndrome: 32 US clinical trials tracked, 14 recruiting.
Acute Respiratory Distress Syndrome is the subject of 32 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is PPD Development, running 4 of these trials.
Enrollment posture brief
Registry condition acute-respiratory-distress-syndrome
OPEN 14 | RECR 44% | LATE 2 | EARLY 16 | RANK #477 | SPON 4
Volume-matched condition peers
Nearest open-share peer: AL Amyloidosis (44% recruiting · 16 trials)
Acute Respiratory Distress Syndrome lists 14 open slots (44% of 32 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Acute Respiratory Distress Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Acute Respiratory Distress Syndrome is recruiting above its size-band peers.
14 of 32 indexed trials (43.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Acute Respiratory Distress Syndrome trials is spread across many organizations.
PPD Development accounts for 4 of 32 trials (12.5%). 26 distinct sponsors appear on at least one study for this condition label.
-
Typical Acute Respiratory Distress Syndrome enrolment sits around 120 participants.
Median target enrolment is 120 among the 32 trials that report a genuine target (sentinel values excluded). 16 of those (50%) plan for fewer than 100 participants.
-
Acute Respiratory Distress Syndrome research is mostly interventional.
26 interventional and 6 observational studies make up this index (81.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
32 total, page 1 of 1
Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome
Children's Hospital Los Angeles
NCT06690801
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
Beth Israel Deaconess Medical Center
NCT06066502
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)
Direct Biologics
NCT05354141
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
PPD Development
NCT06703073
Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS)
BioAegis Therapeutics
NCT05947955
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
University of Michigan
NCT05388708
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
PPD Development
NCT06701656
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
PPD Development
NCT06701682
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
PPD Development
NCT06701669
The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU
Icahn School of Medicine at Mount Sinai
NCT03642002
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
Vasomune Therapeutics
NCT05123755
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
Implicit Bioscience
NCT06513949
Macrophage Programing in Acute Lung Injury: MiniBAL
William Janssen, MD
NCT05767671
The ARISE Study - Use of Vertical Positioning
University of Alabama at Birmingham
NCT07025421
Molecular Epidemiology of Acute Respiratory Distress Syndrome (ARDS)
Massachusetts General Hospital
NCT00006496
Safety and Efficacy Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)
Brigham and Women's Hospital
NCT03799874
Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis
St. Jude Children's Research Hospital
NCT05930418
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
Brigham and Women's Hospital
NCT04870125
suPAR Michigan M2C2 Heterogeneity Validation Cohort Study
ViroGates A/S
NCT07466524
Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Rush University Medical Center
NCT04325906
Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
Fred Hutchinson Cancer Center
NCT01335932
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
Altor BioScience
NCT00879606
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
Apellis Pharmaceuticals
NCT04402060
Mechanical Ventilation, Directed by Esophageal Pressure Measurements, in Patients With Acute Lung Injury
Beth Israel Deaconess Medical Center
NCT00127491
Blood Volume Assessment in COVID-19 and Bacterial Sepsis
NYU Langone Health
NCT04517695
A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome
Healios K.K.
NCT02611609
Feeding the Critically Ill During Phases of Altered Redox Status
University of Illinois at Chicago
NCT03085615
Iloprost Effects on Gas Exchange and Pulmonary Mechanics
University of Oklahoma
NCT01274481
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
Altor BioScience
NCT01438853
Efficacy and Safety of a Lung Recruitment Protocol in Children With Acute Lung Injury
Boston Children's Hospital
NCT00830284
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
Michael A. Matthay
NCT01775774
The ASTERS Study: Assessing the Role of Sphingolipids in AcuTE Respiratory Distress Syndrome (ARDS)
Sturgill
NCT03654352
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 10 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Acute Respiratory Distress Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Acute Respiratory Distress Syndrome trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Acute Respiratory Distress Syndrome page
32 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Acute Respiratory Distress Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- PPD Development sponsors the most Acute Respiratory Distress Syndrome trials on record, review their full trial history before evaluating a specific study. See PPD Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Respiratory Distress Syndrome condition card totals 32 registered trials; most-linked intervention Placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.